| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-07-09 | Nuevolution (Denmark) | scientific advisor | nomination | Technology - Services | Nomination | |
| 2014-07-08 | Cosmo Pharmaceuticals (Italy) undisclosed US public pharmaceutical company (USA) | CB-03-01 | undisclosed skin disorders | licensing |
Dermatological diseases | Licensing agreement |
| 2014-07-08 | Evotec (Germany) Fraunhofer Institute for Molecular Biology and Applied Ecology IME (Germany) | drug discovery programmes | collaboration |
Collaboration agreement | ||
| 2014-07-08 | AstraZeneca (UK), Max Planck Institute of Molecular Physiology (Germany) | ‘satellite unit’ in cardiovascular and metabolic diseases | R&D |
Cardiovascular diseases - Metabolic diseases | R&D agreement | |
| 2014-07-08 | Epilepsy Foundation (USA), Intellimedix (USA - GA) Pfizer (USA - NY) | drug discovery platform for genetic forms of epilepsy | epilepsy, Dravet syndrome | collaboration R&D |
CNS diseases - Genetic diseases - Neurological diseases | Collaboration agreement |
| 2014-07-07 | BioInvent (Sweden) Servier (France) | monoclonal antibodies specific to an undisclosed oncology target | undisclosed cancer | R&D |
Cancer - Oncology | Milestone |
| 2014-07-07 | Bioinvent (Sweden) Bayer (Germany) | antibodies from BioInvent\'s n-CoDeR® libraries | R&D |
Milestone | ||
| 2014-07-07 | Quantum Genomics (France) | Cardiovascular diseases | Nomination | |||
| 2014-07-07 | Portola Pharmaceuticals (USA - CA) Daiichi Sankyo (Japan) | andexanet alfa (modified Factor Xa) | clinical research |
Cardiovascular diseases - Hematologic diseases | Clinical research agreement | |
| 2014-07-03 | Horizon Discovery (UK), Stanford University (USA - CA) | AAV-DJ, proprietary serotype of AAV (Adeno-Associated Virus) | licensing |
Technology - Services | Licensing agreement | |
| 2014-07-03 | UCB (Belgium) Dermira (USA - CA) | Cimzia® (certolizumab pegol) | psoriasis | licensing - development - commercialisation | Autoimmune diseases - Dermatological diseases | Licensing agreement |
| 2014-07-02 | Jazz Pharmaceuticals (Ireland) Sigma-Tau Pharmaceuticals (USA - MD) | Defitelio® (defibrotide) | hepatic veno-occlusive disease | licensing |
Rare diseases | Licensing agreement |
| 2014-07-02 | genOway (France), the Wellcome Trust Sanger Institute (UK), Helmholtz Zentrum Muenchen (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS | conditional knockout (KO) models | licensing |
Technology - Services | Licensing agreement | |
| 2014-07-02 | MDxHealth (Belgium) Miraca Life Sciences (USA - CA) | ConfirmMDx® for Prostate Cancer | prostate cancer | distribution |
Diagnostic - Cancer - Oncology | Distribution agreement |
| 2014-07-02 | Antitope, an Abzena company (UK), Synthon Biopharmaceuticals (The Netherlands) | EpiScreen™ to determine the potential immunogenicity of the antibodies provided by Synthon | development collaboration |
Technology - Services | Development agreement | |
| 2014-07-02 | Impax Laboratories (USA - CA), Actavis (Ireland) | ursodiol tablet, lamotrigine orally disintegrating tablet (ODT) | primary biliary cirrhosis | product acquisition |
Liver diseases - CNS diseases | Product acquisition |
| 2014-07-02 | Amgen (USA - CA) Bind Biosciences (USA - MA) | kinase inhibitor nanomedicine | solid tumors | collaboration development commercialisation |
Cancer - Oncology | Termination of an agreement |
| 2014-07-01 | Curevac (Germany) In-Cell-Art (France) Sanofi Pasteur (France) | mRNA-based vaccine (RNActive® vaccine) | undisclosed | R&D licensing |
Infectious diseases | Licensing agreement |
| 2014-07-01 | Zeltia (Spain) Pharma Mar (Spain) GP Pharm (Spain) | Politrate®/Lutrate® (leuprolide acetate 3.75 mg) | prostate cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-07-01 | MerckSerono (Germany) Pharmstandard (Russia) | Rebif® (interferon beta-1a) | multiple sclerosis | Neurodegenerative diseases | Production agreement |
